Stockscreener 앱 받기
0.5292
1.77%
-0.0151
전일 마감가:
$0.5141
열려 있는:
$0.5241
하루 거래량:
1,424
Relative Volume:
0.00
시가총액:
$6.45M
수익:
$1.85M
순이익/손실:
$-5.56M
주가수익비율:
-0.6979
EPS:
-0.7583
순현금흐름:
-
1주 성능:
-8.01%
1개월 성능:
-7.81%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.5046
$0.5292
1주일 범위
$0.5045
$0.589
52주 변동 폭
$0.4011
$14.09
20 20 Biolabs Inc Stock (AIDX) Company Profile
명칭
20 20 Biolabs Inc
전화
(240) 453-6339
주소
9430 KEY WEST AVENUE, ROCKVILLE
Compare AIDX vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIDX
20 20 Biolabs Inc
|
0.505 | 6.49M | 1.85M | -5.56M | 0 | -0.7583 |
ABT
Abbott Laboratories
|
115.49 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
329.36 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.48 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.81 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.97 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
20 20 Biolabs Inc 주식(AIDX)의 최신 뉴스
Form 8K 20/20 BIOLABS For: 19 August By Investing.com - Investing.com Nigeria
20/20 Biolabs adjourns vote on charter amendment, elects directors at annual meeting - Investing.com
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level - Sahm
20/20 Biolabs Releases Q2 2026 Financial Results - AlphaStreet
20/20 Biolabs Q2 Results: EPS misses, revenue up 36% - scanx.trade
20/20 Biolabs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
20/20 Biolabs, Inc. Common Stock (NASDAQ: AIDX) Stock Price, News & Analysis - kalkine.ca
20/20 Biolabs to host investor webinar; reports best quarterly cancer-test revenue to date - tradingview.com
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour - Yahoo Finance
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy - The Manila Times
20/20 BioLabs meets potential partners in East Asia - Investing.com
20/20 BioLabs meets potential partners in East Asia By Investing.com - Investing.com Canada
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets - GlobeNewswire
20/20 BioLabs seeks East Asia M&A, JV deals to roll up AI blood test assets - scanx.trade
20/20 Biolabs, Inc. Revenue Breakdown – NASDAQ:AIDX - TradingView
20/20 Biolabs Inc. (AIDX) Slides 4.1% as Stock Tests Key Support at $0.47Gap Up Stocks - dars.gov.et
20/20 Biolabs, Inc. (AIDX) stock price, news, quote and history - Yahoo Finance UK
Rokit Healthcare, US 20/20 BioLabs to Co-Develop AI Multi-Cancer Prediction Platform - Seoul Economic Daily
20/20 BioLabs enters standstill pact on preferred stock - Investing.com
20/20 BioLabs Enters Temporary Standstill Agreement Limiting Series E Preferred Stock Conversions - Quiver Quantitative
20/20 BioLabs Announces Standstill Agreement with Streeterville Capital Regarding Series E Convertible Preferred Stock - The Manila Times
Press Release: 20/20 BioLabs Announces Standstill Agreement With Streeterville Capital Regarding Series E Convertible Preferred Stock - Moomoo
20/20 Biolabs, Inc. Signs Standstill Agreement With Streeterville Capital – SEC 8-K Filing Details (July 2026) - Minichart
20/20 Biolabs Received Notice of Noncompliance - TradingView
20/20 Biolabs (Nasdaq: AIDX) signs standstill as Nasdaq flags bid-price issue - Stock Titan
Why Super Micro Computer Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
What Factors Led to 20/20 Biolabs' Dramatic Stock Collapse - Kavout | AI
20/20 BioLabs Highlights Investor Webinar Focused on OneTest™ for Medicare, Serial Biomarker Tracking, and Strong Q2 Revenue Growth - The Manila Times
20/20 BioLabs reports Q2 MCED revenue to be highest to date - Investing.com
20/20 BioLabs highlights OneTest™ strategy for Medicare coverage and reports strong Q2 revenue growth - Pluang
20/20 BioLabs Highlights Investor Webinar Focused on - GlobeNewswire
20/20 BioLabs targets Medicare path as Q2 revenue jumps 30% - scanx.trade
Virax Biolabs | 20-F: Registration statement / Annual report / Transition report - Moomoo
AIDX SEC Filings20/20 Biolabs Inc 10-K, 10-Q, 8-K Forms - Stock Titan
20/20 Biolabs (AIDX) Jumps Nearly 5% as Stock Approaches Key $0.67 ResistanceIchimoku Cloud - dars.gov.et
20/20 Biolabs to present OneTest webinar outlining Medicare pathway, modeling and reimbursement plan - TradingView
OneTest growth vision: 20/20 Biolabs (AIDX) targets Medicare MCED market - Stock Titan
20/20 BioLabs’ Multi-Cancer Early Detection Test Now Available to Evexia Diagnostics' 40,000+ U.S. Practitioners - The National Law Review
20/20 Biolabs Inc. (AIDX) Edges Higher in Low-Price Territory as Support HoldsWyckoff Spring - dars.gov.et
20/20 Biolabs, Inc. Actuals & Estimates (NASDAQ:AIDX) - TradingView
Price to sales forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
Price to book forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
Price to earnings forward of 20/20 Biolabs, Inc. – NASDAQ:AIDX - TradingView
AIDX | 20/20 Biolabs, Inc. Common Executive Compensation - Quiver Quantitative
Large share authorization and new equity plan up for 20/20 Biolabs (AIDX) vote - Stock Titan
20/20 BioLabs Bets on Radical Transparency with Monthly Investor Calls - BriefGlance
20/20 BioLabs Launches Monthly Investor Webinar Series to Enhance Shareholder Communication - Quiver Quantitative
20/20 BioLabs starts monthly webinars, with a OneTest discount for attendees - Stock Titan
20/20 BioLabs Announces Monthly Investor Webinar Series to be Held on the First Wednesday of Each Month - GlobeNewswire
20/20 Biolabs, Inc.(NasdaqCM: AIDX) added to S&P TMI Index - marketscreener.com
AIDX Price Today: 20/20 Biolabs, Inc. Stock Price, Quote & Chart | MEXC - MEXC
20 20 Biolabs Inc (AIDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.32%
0.15%
자본화:
|
볼륨(24시간):